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Abstract
Background:  Intrathecal (IT) gene transfer is an attractive approach for targeting spinal mechanisms of
nociception but the duration of gene expression achieved by reported methods is short (up to two weeks)
impairing their utility in the chronic pain setting. The overall goal of this study was to develop IT gene transfer
yielding true long-term transgene expression defined as ≥ 3 mo following a single vector administration. We
defined "IT" administration as atraumatic injection into the lumbar cerebrospinal fluid (CSF) modeling a lumbar
puncture. Our studies focused on recombinant adeno-associated virus (rAAV), one of the most promising vector
types for clinical use.
Results: Conventional single stranded rAAV2 vectors performed poorly after IT delivery in rats. Pseudotyping
of rAAV with capsids of serotypes 1, 3, and 5 was tested alone or in combination with a modification of the
inverted terminal repeat. The former alters vector tropism and the latter allows packaging of self-complementary
rAAV (sc-rAAV) vectors. Combining both types of modification led to the identification of sc-rAAV2/l as a vector
that performed superiorly in the IT space. IT delivery of 3 × 10e9 sc-rAAV2/l particles per animal led to stable
expression of enhanced green fluorescent protein (EGFP) for ≥ 3 mo detectable by Western blotting, quantitative
PCR, and in a blinded study by confocal microscopy. Expression was strongest in the cauda equina and the lower
sections of the spinal cord and only minimal in the forebrain. Microscopic examination of the SC fixed in situ with
intact nerve roots and meninges revealed strong EGFP fluorescence in the nerve roots.
Conclusion: sc-rAAVl mediates stable IT transgene expression for ≥ 3 mo. Our findings support the underlying
hypothesis that IT target cells for gene transfer lack the machinery for efficient conversion of the single-stranded
rAAV genome into double-stranded DNA and favor uptake of serotype 1 vectors over 2. Experiments presented
here will provide a rational basis for utilizing IT rAAV gene transfer in basic and translational studies on chronic
pain.
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Background
The spinal cord (SC) is an important center of nociceptive
signal processing and a notable anatomic target for anal-
gesic therapy development. Delivery of drugs to the SC by
common systemic routes, i.e. pills taken by mouth,
patches applied to the skin, and injections given intrave-
nously has two potential pitfalls: Firstly, the drug may not
cross the blood brain barrier (BBB) if it is hydrophilic
and/or has a high molecular weight. Secondly, once across
the BBB, it may cause untoward effects by acting indis-
criminately on supraspinal structures of the central nerv-
ous system (CNS). Intrathecal (IT) delivery addresses
these issues by targeting drugs anatomically to the SC.
While IT pharmacokinetics may vary depending on the
drug's lipophilicity, its stability in the cerebrospinal fluid
(CSF), the flow pattern of CSF in an individual animal or
patient, and other modifying factors [1], this form of
administration has in practice been found to allow spe-
cific spinal targeting of a variety of agents. It has been used
in laboratory animals for decades [2,3] and proven to be
efficacious in patients [4]. However, the need to implant
and maintain an IT catheter and to infuse drugs through a
pump system to achieve a long-term effect requires a spe-
cialized medical team [5] and can be complication-ridden
[6-8]. This has effectively prevented the adoption of IT
pain therapy in large groups of patients who could bene-
fit, e.g. many with advanced cancer under the primary care
of oncologists. In the investigational setting, targeting of a
newly identified spinal pain mechanism may be curbed
by the lack of an appropriate small molecule or recom-
binant protein. In many such instances the corresponding
cDNAs are available and expressing them IT would suffice
to proceed with a particular experiment or a translational
clinical study.
IT gene transfer has been investigated by several groups as
an alternative to IT peptide or protein delivery [9-14]. The
cells reached with current gene vectors in the IT space, e.g.
meningeal fibroblasts, are not directly involved in nocice-
ptive signal processing but can assume an active role by
secreting a relevant peptide or protein (encoded by the
gene vector) into the CSF. The peptide or protein can then
act in a paracrine fashion on cells in the spinal cord as
shown in IT gene transfer experiments for β-endorphin
and interleukin (IL)-10 [10-12]. Different types of gene
vectors have been used in the IT space: liposomes [15],
plasmid DNA with electroporation [13,14], plasmid DNA
in hypertonic diluent [16], adenovirus [9-11], and adeno-
associated virus (AAV) [12]. While all studies reported
some promising evidence of transgene activity, the dura-
tion of expression never exceeded two weeks (except for a
protocol using repeat vector administration [16]). Thus,
long-term gene expression has not been achieved with IT
delivered vectors. For other body sites, the problem of
limited duration of transgene expression has been a com-
mon finding and a favorite topic of gene therapy research.
Few vector systems have emerged that can often overcome
this problem, in particular vectors derived from AAV, len-
tiviruses, or herpes simplex viruses (HSV). Recombinant
AAV (rAAV) is popular because it may be a particularly
safe choice. It is derived from the adeno-associated virus
that commonly infects humans without ever causing
symptoms or a disease. rAAV vectors are engineered to be
devoid of viral genes, integrate rarely into chromosomes,
and appear to pose little risk to the genomic integrity and
growth control mechanisms of primary cells. Clinical
safety and efficacy data on rAAV is currently accumulating
from several clinical trials for retinal degeneration, hemo-
philia, Parkinson's, and other diseases [17].
The overall goal of the present study was to develop IT
gene transfer yielding true long-term expression. We
defined this as stable expression for at least three months
following a single vector administration. Many chronic
pain models, e.g. the chronic constriction injury model of
neuropathic pain induce alterations in nociceptive behav-
iour for approximately two months thereby exceeding the
two-week limit of previous reports on IT gene transfer but
staying within the time frame set here. We defined "IT"
administration as atraumatic injection into the lumbar
CSF, i.e. modelling a lumbar puncture (LP). A LP is a clin-
ically safe procedure because it does not sever the SC. It
thereby differs from reports "subarachnoid" vector deliv-
ery achieved by a laminectomy at a higher SC level fol-
lowed by blind transdural vector injection with a sharp
pipette [18], which leads to highly localized gene expres-
sion consistent an intraparenchymal injection into the SC
[19]. We focused on AAV based vectors even though a
recent study in this journal had reported that IT rAAV2
expressed only for two weeks [12]. We hypothesized that
the IT performance of the conventional single-stranded
rAAV serotype 2 used in the published studies was limited
by a failure of the capsid protein to mediate uptake and
intracellular virus particle processing and/or by a failure
of the cellular machinery to mediate second-strand DNA
synthesis, which is a requirement for gene expression
from a single-stranded DNA parvovirus like AAV. We
tested these possibilities using rAAV vectors pseudotyped
with capsid proteins of the serotypes 1, 2, 3, and 5 and by
employing a recently developed rAAV variant that is pack-
aged as double-stranded DNA, a "self-complementary"
rAAV (sc-rAAV). By combining both approaches, we
found that sc-rAAV serotype 1 has superior IT gene trans-
fer capability mediating reliable and stable IT gene expres-
sion for at least four months in rats.Molecular Pain 2006, 2:4 http://www.molecularpain.com/content/2/1/4
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Results
Modification of rAAV capsid and ITR for improved IT gene 
transfer
rAAV2 is the best characterized type of rAAV vector and
has been reported to mediate long-term gene expression
in the brain, liver, muscle and other organs [20]. We pre-
pared rAAV2 expressing enhanced green fluorescent pro-
tein (EGFP) under the control of the CMV promoter and
injected it IT into twenty rats at doses up to 1010 viral par-
ticles per animal. Ten control animals were injected with
phosphate buffered saline (PBS). Animals were sacrificed
after four weeks or four months, because rAAV2 has been
reported to reach maximal expression levels in this time
frame in other organs [21]. SC tissue from half of the ani-
mals was prepared for Western blotting (fresh frozen at -
80°C) and from the other half for microscopy (requiring
formalin fixation). No EGFP could be detected by Western
blotting of tissue pooled from the upper and lower half of
the SC or by extensive review of sections from all SC seg-
ments including the cauda equina (CE) using laser scan-
ning microscopy (data not shown).
Gene transfer with AAV2-derived vectors can be improved
for certain applications by "pseudotyping" the recom-
binant vectors with capsids of other AAV serotypes while
retaining the AAV2-derived inverted terminal repeats
(ITR) and other elements of the viral genome [22,23]. The
resulting vectors are designated rAAV2/l, rAAV2/2, rAAV2/
3 and so on indicating the capsid serotype. We tested
rAAV2/l and rAAV2/5 vectors IT but were unable to detect
green fluorescent protein expression by laser scanning flu-
orescent microscopy. Repeating the experiment with
rAAV2/l and rAAV2/5 vectors expressing canine factor IX
(a generous gift from Dr. H. Chao) and measuring trans-
gene levels in the CSF by ELISA did not provide any evi-
dence of transgene expression (data not shown). We
reasoned that the target tissues that are accessible to gene
vectors in the IT space might lack cellular factors required
for second-strand DNA synthesis. AAV is a single-stranded
DNA parvovirus and synthesis of a complementary DNA
strand is an absolute requirement in the life-cycle of wild-
type AAV and for expression of genes encoded by any
recombinant variety [24]. To test if getting around this
step would facilitate IT gene expression, we prepared self-
complementary rAAV (sc-rAAV) vectors that contain a
deletion in the D-region of one of the ITRs. During viral
replication, this deletion prevents nicking of the newly
synthesized rAAV genome by the viral protein rep thereby
allowing efficient production and packaging of dimeric,
double-stranded rAAV genomes into the recombinant
viral particles [25]. We prepared sc-vectors of four differ-
ent serotypes, sc-rAAV2/l, sc-rAAV2/2, sc-rAAV2/3, and sc-
rAAV2/5, and tested them in small groups of animals
using 3 × l09 sc-rAAV particles per IT injection as for the
prior experiments. Animals were sacrificed after four
Improved IT gene transfer by pseudotyping sc-rAAV vectors  with the serotype 1 capsid Figure 1
Improved IT gene transfer by pseudotyping sc-rAAV 
vectors with the serotype 1 capsid. (A.) sc-rAAV vec-
tors packaged with capsids of the serotypes 1, 2, and 5 were 
evaluated. Four months after IT vector application (3 × l09 
particles/animal), animals were sacrificed, the lower half of 
the SC including the CE and the surrounding meninges was 
harvested, frozen at -80°C, pulverized, and subjected to 
Western blotting (20 µg protein loaded per lane). A repre-
sentative Western blot demonstrating EGFP expression in 
rats injected with vectors of the serotypes 1 and 5 is shown. 
No expression was seen with serotype 2 or in negative con-
trol rats injected with PBS (marked as '-'). Actin served as a 
loading control. (B.) One month after IT vector administra-
tion expression with serotype 1 was demonstrable in five out 
of six rats. The failure to detect EGFP expression in one rat 
may have been related to IT bleeding at the time of catheter 
placement and/or to inattention in harvesting the nerve roots 
of the CE, which were included with the lumbar segments of 
the SC in this experiment. '(+)' indicates expression in the SC 
of an EGFP-transgenic mouse, which served as positive con-
trol. Equal loading of lanes was confirmed by protein staining 
of the membranes (not shown). (C.) qPCR demonstrated sig-
nificantly higher IT expression with serotype 1 (● ) compared 
with serotype 2 (■ ) (p < 0.01). The scale of the ordinate is 
inverted indicating the threshold cycle Tc with lower cycle 
numbers corresponding to higher expression. No expression 
was seen in PBS controls (▲ ) as indicated by Tc > 40. The Tc 
for the house keeping gene ubiquitin varied little and was not 
different between the groups.Molecular Pain 2006, 2:4 http://www.molecularpain.com/content/2/1/4
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months and the lower half of the SC (lumbar segments
and cauda equina) was analyzed by Western blot. sc-
rAAV2/l resulted in strong EGFP expression and sc-rAAV2/
5 in weak expression. No expression was seen with sc-
rAAV2/2 or sc-rAAV2/3 (not shown) or in PBS injected
control animals as illustrated in a representative Western
blot (figure 1A). To test if expression could be detected at
an earlier time point, we sacrificed animals one month
after IT sc-rAAV2/l injection and found strong EGFP
expression in the majority of SC samples. Expression lev-
els were in the range of 1% of EGFP-transgenic mice used
as a positive control in this part of the study (figure 1B).
To confirm that the improved outcome with sc-rAAV2/l
over sc-rAAV2/2 was indeed related to the serotype, we
repeated the experiments in two new groups of animals
with newly prepared vectors. We used quantitative reverse
transcriptase polymerase chain reaction (qPCR) to quan-
titate low levels of sc-rAAV2/2 expression that had not
been detectable by Western blot. As shown in figure 1C,
qPCR of the house keeping gene ubiquitin showed little
inter-animal variation and no difference between groups.
qPCR from control SC from PBS injected animals did not
reach the detection threshold (at the maximum of 40
cycles). Expression with serotype 1 was significantly
higher than with serotype 2 (p < 0.01) confirming the
prior finding.
Low levels of transgene expression in the brain following IT  sc-rAAV delivery Figure 2
Low levels of transgene expression in the brain fol-
lowing IT sc-rAAV delivery. (A.) EGFP expression in the 
brain was undetectable by Western blotting. Rats were 
injected IT with sc-rAAV vectors of different serotypes as 
indicated (3 × l09 particles/animal). (B.) Low levels of EGFP 
expression could be detected in the brain by qPCR (sc-
rAAV2/l, 3 × l09 particles/animal). The standard curve dem-
onstrates that the median Tc for EGFP expression in the 
brain corresponded to only 2 × 10-4-fold the expression 
found in the lower SC.
Anatomic distribution of transgene expression along the spi- nal axis Figure 3
Anatomic distribution of transgene expression along 
the spinal axis. EGFP expression was consistently higher in 
the cauda equina (CE) than in the rostral parts of the SC. The 
CE and SC were harvested as one tissue block with the 
meninges intact, dissected into four portions, CE, lumbar SC 
("L"), thoracic SC ("T"), and cervical SC ("C") and subjected 
separately to Western blotting. Quantitation of expression 
levels demonstrated a significant difference between the CE 
and the adjacent lumbar SC (p < 0.01).Molecular Pain 2006, 2:4 http://www.molecularpain.com/content/2/1/4
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Transgene expression in the brain after IT vector delivery
One of the goals of IT gene delivery is to minimize expo-
sure of the forebrain to the effects of the vector-encoded
transgene. In our study, no EGFP expression could be
detected in the brain by Western blot (figure 2A). Based
on experiments with recombinant EGFP protein, we esti-
mated that the sensitivity of the Western blot was approx-
imately 2–20 pg/sample under optimized conditions and
would allow us to detect levels in the brain that are
approximately 10-2-fold the average level in the cauda
equina. In order to be able to detect lower levels and to
make quantitative comparisons over a wider range, we
used the qPCR introduced in the prior figure establishing
a standard curve demonstrating linearity over a 105-fold
range. Low levels of EGFP were detected in the brain,
which were 2 × 10-4-fold the levels detected in the lumbar
third of the SC (figure 2B). Of note, we used the lumbar
portion of the SC in this experiment rather than the CE,
because we found it difficult to isolate sufficient quanti-
ties of high-quality RNA from the CE. As described in the
next section, expression is highest in the CE (as assessed
by Western blotting) suggesting that there is a greater than
105-fold difference in expression levels between the lower
IT space and the forebrain.
Anatomical localization of transgene expression
Quantitative Western blotting demonstrated that EGFP
expression was highest in the CE followed by the lower
and then the upper sections of the SC forming an appar-
ent gradient from the site of vector delivery in the area of
the conus medularis to the rostral end of the SC (figure
3A).
We next localized EGFP expression in microscopic sec-
tions of the SC by laser-scanning microscopy. Using SC
tissue from EGFP-transgenic and control mice as positive
and negative controls, we established settings that sup-
pressed background fluorescence and/or identified areas
of unspecific fluorescence by their broader emission spec-
trum. Following an open label training period, the princi-
pal microscopist in the team (NMH) was given 15 slides
in a blinded fashion that had been selected randomly
from a collection of two hundred slides by a person not
involved in the study and not knowledgeable of the ani-
mal's group assignment. Slides included sections from all
parts of the SC and CE and were in roughly equal propor-
tion from animals injected either with sc-rAAV2/l or with
PBS. Examination of the slides under these conditions led
to the correct identification of 7 of 7 tissue samples as pos-
itive, i.e. prepared from rats injected IT with sc-rAAV2/l
and of identification of 8 of 8 samples as negative, i.e. pre-
pared from rats injected with PBS. If the outcome of such
an experiments is determined by chance, it follows a bino-
mial distribution since the outcome is binary (correct/
incorrect), the experiment consists of independent trials
(each slide was evaluated independently of the outcome
for the previous slide), the number of trials is fixed in
advance, and an equal probability of success for each indi-
vidual trial (each slide) exists, which is similar to the flip
of a fair coin = 0.5. Thus, we calculated that the likelihood
of 15 consecutive successes (= correct identification of
slides) was (l/2)15 = 6.1 × 10-5, which means that the result
is highly significant (p < 0.0001) and unlikely to conse-
quence of chance. This argument provided us with confi-
dence that the fluorescence observed under these
Cellular localization of transgene expression Figure 4
Cellular localization of transgene expression. Confocal microscopy demonstrated EGFP-expression in the nerve roots. 
The left panel provides an anatomic overview of a lumbar section through the spinal cord obtained with transmission light at a 
low magnification. The middle panel shows EGFP fluorescence (excitation wave length 488 nm, emission wave length 505–530 
nm). The right image is a fusion of the fluorescence image with a transmission light micrograph of the same area. The insert 
depicts a detail at higher magnification. Images were obtained on an LSM 510 META confocal microscope.Molecular Pain 2006, 2:4 http://www.molecularpain.com/content/2/1/4
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conditions reflected a true gene transfer effect. The major-
ity of specific fluorescence was observed in the nerve
roots. A typical example from the lumbar SC is shown in
figure 3B. This finding is consistent with the Western blot
finding of figure 3A, namely that the portion of the SC
with the greatest density of nerve roots, the CE, expresses
EGFP at the highest level. We cannot exclude EGFP expres-
sion in other areas including possibly the DRG. In fact, on
occasion we had the impression that EGFP could also be
observed in meningeal fibroblasts and occasionally in
cells intrinsic to the SC. These possibilities are currently
under investigation with higher titer vectors preparations
and improved detection techniques based on immuno-
histochemistry.
Long-term gene expression
The major objective of this study was to identify a vector
for IT gene transfer capable of long-term gene expression,
i.e. beyond the two-week time point reported by all previ-
ous studies on IT gene transfer. As shown in figure 1A, we
initially identified sc-rAAV2/l as a good candidate vector
based on screening experiments employing a four
months-time point. To formalize this finding we deter-
mined the level of EGFP expression by quantitative West-
ern blotting of CE tissue at several time points after IT
administration of sc-rAAV2/l. As shown in figure 4, signif-
icant expression was detectable one week after vector
delivery followed by a further increase. Gene expression
then reached a plateau by four weeks and persisted
unchanged at that level for at least twelve weeks. This time
course, i.e. a slow onset of gene expression over the course
of several days to a few weeks followed by persistence of
gene expression for many months is typical of successful
AAV gene transfer experiments in other organs. Self-com-
plementary AAV vectors as used in this study have been
reported to have a faster onset of gene expression than
conventional, single-stranded AAV vectors. Therefore, we
repeated the first two time points in a new group of ani-
mals. Again, we found that expression at one week was
lower than expression at four weeks.
Discussion
The present study addressed the question if rAAV vectors
constitute a notable improvement upon other gene vec-
tors currently used for IT rat studies on chronic pain, in
particular, if rAAV vectors can mediate efficient long-term
gene expression in this paradigm. To overcome known
inadequacies of conventional rAAV2 in the IT space, we
tested alterations to its two principal components, the
capsid and the genome. Specifically, we pseudotyped
rAAV vectors with capsids from various serotypes and
modified its genome to allow high-efficiency packaging of
double-stranded (self-complementary, "sc-") instead of
single-stranded recombinant genomes. While the parent
vector, rAAV2 performed poorly yielding low expression
levels that were detectable only by qPCR, a vector carrying
both above modifications, sc-rAAV2/l performed favoura-
bly. EGFP marker gene expression was reproducibly
detected in vivo by qPCR and Western blotting and under
blinded conditions by confocal microscopy. Transgene
levels were found by Western to be highest in the CE and
the caudal SC, which was consistent with our microscopic
observations that the nerve roots displayed strong specific
EGFP fluorescence. Expression occurred as early as one
week, increased subsequently, and remained stable
between four and twelve weeks. These results supported
the underlying hypothesis that the poor performance of
rAAV2 vectors resulted from an inability of potential tar-
get cells in the rat IT space to mediate binding of serotype
2 capsids and/or to provide the machinery for efficient
conversion of the single-stranded vector genome into a
double-stranded DNA template ready to be transcribed.
While further questions regarding the IT properties of
these vectors could be addressed with additional marker
gene studies as discussed below, the presented data
should allow the efficient design of improved vectors for
IT delivery in chronic pain models, e.g. since completion
of the study we were able to construct an sc-rAAV2/l vector
expressing a secreted analgesic gene product that we could
detect in CSF from the lumbar IT space and the cisterna
magna two months after IT vector application (data not
shown).
The utility of gene therapy for a specific medical applica-
tion depends critically on how well the vector properties
match the requirements set forth by the molecular target.
IT gene therapy for pain was proposed a decade ago in a
report on an artificial opioid gene with paracrine spinal
analgesic activity [26]. When the gene was delivered IT by
an adenovirus vector [10] or by grafting of retrovirally
transduced fibroblasts [27] it suppressed nociceptive
behaviour in rats. However, the approach had shortcom-
ings that discouraged further exploration in pre-clinical
studies. Firstly, it did not allow for regulation of the ther-
apeutic gene following vector delivery, which may have
been desirable in this case, because opioid medications
typically require dose adjustments in the clinical setting.
Secondly, gene expression and thus analgesic activity was
not sustained beyond two weeks due to the gene transfer
technology, namely an inflammatory response in the case
of the adenoviral vectors and promoter shut-down in the
case of the Moloney-type retroviral vectors. In the early era
of gene therapy research cases like this – an appealing
idea, support through a "proof of principle" study, then
the realization that no available vector could do the job
well enough – were common precipitating a call to pursue
"The basic science of gene therapy" [28], i.e. a focus on
studying the vectors in order to match their biological
properties to a potential application or to improve their
shortcomings. In the area of gene therapy for pain Drs.Molecular Pain 2006, 2:4 http://www.molecularpain.com/content/2/1/4
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Glorioso, Fink, Yeomans et al. took the former approach
by building their pre-pro-enkephalin gene transfer around
the natural ability of HSV to infect peripheral sensory
nerves and be retrogradely transported to the DRG [29-
31]. Others including ourselves pursued the latter
approach, i.e. searching for an improved vector system to
achieve better gene delivery by the administration route
that appears most appropriate for targeting spinal pain
mechanisms, namely IT delivery. In a recent review article
we provided an account of which vector types were tested
by ourselves and others for IT use failing to provide sus-
tained expression, why IT AAV appeared promising
despite the limitations encountered in published studies,
and which molecular targets characterized by others may
be most suitable for IT therapy of chronic pain states with-
out requiring regulation of the therapeutic gene or dose
adjustments except through the delivered dose of vector
[32]. In the present article, we show the result of our
search for a better vector providing the first report of long-
term gene expression after a single IT administration of
any vector type. The approach should be useful in its
present form for studies in rats requiring chronic delivery
of a secreted transgene product into the spinal CSF, e.g. IL-
10 for the suppression of glial activation as proposed by
Drs. Milligan, Watkins et al. [11,12,33,34]. The AAV vec-
tor dose used in this study, 3 × l09 viral particles per ani-
mal could be titrated downwards if lower transgene levels
are desired that are in line with levels obtained with naked
DNA/plasmid gene transfer (unpublished). AAV vector
doses can also be increased to ≥ 1011 viral particles per rat
with well purified/concentrated AAV preparations while
keeping the IT injection volume constant. This should
provide flexibility for different therapeutic genes and
experimental goals.
Extrapolating from the experience with rAAV delivery to
other body sites (muscle, liver, brain), it can be expected
that IT delivered rAAV does not induce cellular immunity
to vector component in rodents and will have minimal or
no effects ascribable to the gene transfer procedure
thereby permitting a clean evaluation of the transgene of
interest in mice or rats. rAAV appears to be among the saf-
est gene transfer options for potential use in patients and
is currently undergoing clinical evaluation for retinal
degeneration, hemophilia, Parkinson's and other diseases
[17]. It may therefore be a candidate vector for future
translational studies serving as a research tool to validate
whether the manipulation of a specific spinal molecular
mechanism that is operative in rodent models is similarly
important in patients, e.g. glial activation in neuropathic
pain. In order to evaluate rAAV for such use, a number of
hypotheses need to be tested in large animals, which are
related to the vector technology. Up-scaling experiments
to large animals has been a critical benchmarks in other
fields of gene therapy research, e.g. hemophilia, an area in
which one of us (CEW) has been closely involved with
this issue [35,36]. Establishing in pigs, dogs, or non-
human primates whether a serological and/or cellular
immune response occurs to IT rAAV and, perhaps more
importantly, to a specific transgene product of interest
will be critical [37]. In addition such experiments would
allow to determine gene product levels, biodistribution,
and target cells of IT rAAV in a model that appears more
realistic for humans than rodents. Hopefully, experiments
as presented and proposed here will provide a rational
basis for utilizing gene transfer in basic and translational
studies on chronic pain.
Methods
Animals and vector application through an IT catheter
All procedures involving animals were reviewed and
approved by the Institutional Animal Care and Use Com-
mittee (IACUC) and followed national guidelines and
requirements set forth by the National Institutes of Health
(NIH), Bethesda, MD, USA. Adult male Sprague-Dawley
rats of 300–350 g body weight were used.
Intrathecal catheterization was performed as originally
developed by Yaksh et al. and described in a recent review
on IT catheterization and drug delivery in the rat [3,38]. In
brief, rats were anesthetized with isoflurane and placed in
a stereotactic frame. The occipital neck area was shaved
and sterilized with betadine solution (Purdue Fredrick,
Stamford, CT, USA). A skin incision of approximately 1
cm length was made and the atlanto-occipital membrane
was surgically exposed using blunt preparation technique
with meticulous attention to hemostasis. A l-2 mm long
incision was made in the atlanto-occipital membrane cut-
ting the dura and arachnoid membrane and exposing the
subarachnoid space. Next sterile catheter consisting of
slightly pre-stretched PE10 polyethylene tubing (Intra-
medic, Becton Dickinson and Company, cat. no. 427400)
was inserted through the cisterna magna into the IT space
and advanced to the caudal end of the SC. rAAV particles
suspended in phosphate buffered saline (PBS) was then
injected in a total volume of 15 µl at constant flow rate
over one min (minute). An equal volume of PBS without
virus was injected in control animals. 3 × l09 viral particles
were used for all experiments except for some of the rats
used for confocal microscopy, which were injected with
1× or 3 × l010 viral particles. The catheter was then slowly
withdrawn, the neck muscles approximated with surgical
sutures and the skin closed with 9 mm wound clips (Clay
Adams Brand, Becton Dickinson, no. 427631). Animals
were placed in a recovery cage and monitored until they
resumed normal activity. Animals were examined postop-
eratively and daily thereafter for signs of neurological def-
icits or any kind of distress and animals found to display
any such signs were sacrificed in accordance with the
IACUC approved procedures.Molecular Pain 2006, 2:4 http://www.molecularpain.com/content/2/1/4
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Quantification of gene expression by Western blotting and 
reverse transcriptase PCR
Animals were sacrificed by carbon dioxide inhalation. The
SC and CE were immediately removed with the menin-
geal linings intact and snap frozen on a metal block
cooled I liquid nitrogen. The SC/CE tissue block was then
subdivided into two or four portions along the rostral-
caudal axis as indicated in the respective figure legend and
pulverized in a ceramic grinder under liquid nitrogen.
For quantification of EGFP protein by Western blotting,
an aliquot of the pulverized tissue was homogenized in
RIPA buffer on ice with a high speed tissue homogenizer
(Tissuemizer, Fisher Scientific) and centrifuged for 30 min
at 13,000 rpm at 4°C allowing elimination of cell debris
found in the pellet. The protein concentration of the
supernatant was determined with the DC Protein Assay
Kit II according to the manufacture's instruction (Bio-
Rad). Spinal cord tissue of an EGFP transgenic mouse or
recombinant EGFP protein (Clontech) was used as a pos-
itive control and quantitative standard. 20 ug total protein
was electrophoresed in a 12% SDS-polyacrylamide gel
and electroblotted onto a nitrocellulose membrane. The
membranes were incubated in blocking solution contain-
ing 5% nonfat milk in 1× Tween Tris-buffered saline.
Membranes were then incubated with the mouse mono-
clonal antibody against EGFP (JL-8, BD-Biosciences, dilu-
tion 1:1000) for 2 h at room temperature. Membranes
were washed and incubated anti-mouse horse-reddish
peroxidase-conjugated antibody (Amersham, dilution
1:2500) for 1 h at room temperature. Membranes were
again washed and then covered with the Lumi-Light West-
ern Blotting Substrate (Roche). The resulting chemilumi-
nescence was then digitally recorded using the a cooled
camera luminescent imaging system (LAS-3000, Fuji).
For quantification of EGFP RNA, an aliquot of the pulver-
ized frozen tissue was dissolved and thereby thawed in
RLT buffer followed by isolation of total RNA using a
mini-column based kit (RNeasy Mini Kit, Qiagen). Single-
stranded cDNA was synthesized in a 25 µl reaction from 1
µg total RNA using 2.5 ul 10× buffer, 10 ul MgC12, 2.5 ul
dNTP, lul oligo dT, 0.5 ul Rnasin, 0.8 µl RT, and nuclease
free water at 25°C for 10 min, and 45°C for 60 min fol-
lowed by inactivation at 95°C for 5 min (Reserve Tran-
scription Kit, Promega).
Quantitative PCR was performed in triplicates on an ABI
PRISM 7900HT thermocycler (Applied Biosystems) using
the fluorophore SYBR Green (Applied Biosystems). A
Time course of IT gene expression Figure 5
Time course of IT gene expression. (A.) Gene expression was detectable in the CE one week after IT delivery of sc-
rAAV2/l (3 × l09 particles/animal). Expression levels increased further after one week and reached a plateau with stable expres-
sion at four and twelve weeks, the longest time point tested. Shown is the mean and SEM of expression levels determined by 
quantitative Western blotting with group sizes of seven to nine animals as indicated (). No expression was seen in PBS 
injected control rats (Ќ). (B.) The one- and four-week time points were repeated in a second group of animals to confirm the 
rise in EGFP levels during this time frame (❍ ). PBS controls showed again no detectable expression ().Molecular Pain 2006, 2:4 http://www.molecularpain.com/content/2/1/4
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cDNA amount corresponding to 15 ng of RNA was used
per reaction in a total volume of 10 µl. The concentration
of each primer was 0.4 µM. Primers for EGFP were: For-
ward 5'-AGC AAA GAC CCC AAC GAG AA-3', reverse 5'-
GGC GGC GGT CAC GAA-3'. Primers for rat ubiquitin
were: Forward 5'-GTG GCT ATT AAT TCT TCA GTC TGC
AT-3', reverse 5'-GCA AAT GGC TAG AGT GCA GAG TAA-
3'. Following incubation at 50°C for 2 min and denatura-
tion at 95°C for 10 min 40 thermal cycles were executed
as follows: 95°C × 15s, 60°C × 1 min.
Tissue slide preparation and confocal microscopy
Animals were anesthetized with Chloral Hydrate 30%
(Sigma, Lot no. 045K0664) dissolved in sterile water and
injected intraperitoneally at a volume of 0.8–1.4 mL,
which was repeated if needed to achieve deep anesthesia.
Animals were then perfused transcardially for 1 min with
freshly prepared ice-cold paraformaldehyde 1% (PFA,
Electron Microscopy Sciences, catalogue number 19210)
in PBS, followed by perfusion with PFA 4% and glutaral-
dehyde 0.125% (Electron Microscopy Sciences, 50% solu-
tion, cat. no. 16310) for 13 min. The spinal column was
then removed by first exposing it in its entire length from
the cisternal membrane to 14 cm caudally by anatomical
dissection of the dorsal muscles and by then transecting of
the ribs and other adjacent tissue. The spinal column with
the SC, CE and meninges intact was then post-fixed in PFA
4% for 24 h. The spinal column was then subjected to a
decalcification protocol consisting of slow-motion shak-
ing of the tissue at 4°C in a buffer of 10% ethylene
diamine tetra acetic acid (EDTA, Sigma, cat. no. E5134)
prepared in distilled water and adjusted to a pH of
approximately 7.4–7.6. The EDTA buffer was changed
daily during the first two weeks followed by changes every
other day until the bone of the spinal column was com-
pletely decalcified at 4 weeks. The tissue was then cryopro-
tected by immersion in increasing concentrations of
sucrose (Sigma, Lot no. 62H0607) dissolved in PBS,
namely at concentrations of 10% × 2 h, 20% × 2 h, and
30% overnight. The tissue was the dissected in smaller
blocks, embedded in Optimal Cutting Temperature Com-
pound (OCT, Tissue-Tek, 4583, Sukura) or Tissue Freez-
ing Medium (TBS, Electron Microscopy Sciences, cat. no.
72592). Tissue sections of 50–60 microns were then cut
on a Cryostat (2800 Frigocut E, Reichert-Jung), thaw-
mounted on pre-treated glass slides (50 × 75 mm slides,
Brain Research Laboratory), gently PBS-washed, and pro-
tected with a cover glass (48 × 60 mm no.l, cat. no. 4860-
1, Brain Research Laboratory) using mounting medium
(Vectashield hardset H-1400, Vector Laboratories).
Microscopic examination of tissue slides was performed
with a confocal laser-scanning microscope (LSM 510
META, Zeiss Inc.). An excitation wavelength of 488 nm
was used (Argon laser, intensity 5%). To detect EGFP, flu-
orescence images were recorded at an emission wave-
length of 505–530 nm. Unspecific fluorescence was
visualized at >560 nm. Settings for gain and offset were
optimized using positive and negative control tissue and
open label samples. Subsequently all settings were kept
constant for the blinded examinations of slides.
rAAV production
All rAAV vectors were produced, purified, and titered as
previously described [35]. The sc-rAAV/EGFP DNA tem-
plates utilized for encapsidation in AAV 1, 2, and 5 cap-
sids were derived from plasmid pHpa-trs-SK developed by
one of the co-authors [25]. The AAV1 and AAV5 packaging
plasmids were generously supplied through the Gene
Therapy Center, University of North Carolina, Chapel Hill
(Dr. Jude Samulski).
Statistical methods
The significance level for the scoring of slides by confocal
microscopy under blinded conditions was calculated
based on the binomial distribution, since the data type in
this case was categorical (success/failure = correct/incor-
rect scoring of a slide), trials were independent (each slide
was evaluated independently of the outcome for the pre-
vious slide), the number of trials was fixed in advance (15
coded slides handed to the microscopist), and the proba-
bility of success was uniformly 0.5 for each individual
trial. If all trials n are successful as in our case, the signifi-
cance level is calculated in a simplified way as (probability
of success)n.
The data of all other experiments was continuous (i.e.
non-categorical), unpaired, and of an unknown distribu-
tion type. Therefore a two-sided, non-paired Wilcoxon-




BBB: blood brain barrier
CE: cauda equina
CNS: central nervous system
EGFP: enhanced green fluorescent protein
HSV: herpes simplex viruses
IACUC: Institutional Animal Care and Use Committee
IT: intrathecal
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min: minute
PBS: phosphate buffered saline
qPCR: quantitative polymerase chain reaction
rAAV: recombinant adeno-associated virus
SC: spinal cord
sc-rAAV: self-complementary recombinant adeno-associ-
ated virus
sc-rAAV2/l: self-complementary recombinant adeno-asso-
ciated virus type 2 pseudotyped with a capsid from sero-
type 1 (= packed in capsid protein from AAV1)
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